Journals / Turkish Journal of Medical Sciences / 2020 / Cilt: 50 - Sayı: 1

Multicenter study of levodopa carbidopa intestinal gel in Parkinson's disease: the Turkish experience

Pages
66–85
Publication Date
2020-01-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Cronbach's alpha was 0.795 and the intraclass correlation coefficient was reliable for the items.Conclusion: As detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG treatment in many aspects of the disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Our purpose was to determine the efficacy of levodopa carbidopa intestinal gel LCIG in a series of Turkish patients with Parkinson's disease PD .
📊
Key Findings & Data:Materials and methods: We had telephone calls with 54 patients from 11 neurology centers who were on LCIG treatment, and 44 patients or their caregivers were included in an eight-item survey between September 2015 and June 2016.
💡
Conclusion & Impact:Cronbach's alpha was 0.795 and the intraclass correlation coefficient was reliable for the items.Conclusion: As detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG treatment in many aspects of the disease.
🔬Design:Survey & Empirical Study
📍Scope:2015 Verileri
⚙️Variables:Parkinson's disease · levodopa carbidopa intestinal gel · efficacy

Abstract

Background/aim: Our purpose was to determine the efficacy of levodopa carbidopa intestinal gel LCIG in a series of Turkish patients with Parkinson's disease PD . Materials and methods: We had telephone calls with 54 patients from 11 neurology centers who were on LCIG treatment, and 44 patients or their caregivers were included in an eight-item survey between September 2015 and June 2016. The reliability and validity of the survey were evaluated with intraclass correlation coefficients for every question separately.Results: Average age of the patients were 63.48 and the duration of PD was 12.79 years. Average LCIG treatment period was 15.63 months. Percentages of the patients who reported they were `better' after LCIG treatment were as follows: 80% for time spent off, 55% for dyskinesia, 65% for tremor, 85% for gait disorder, 50% for pain, 50% for sleep disorders, 42.5% for depression, 32.5% for incontinence, and 70% for activities of daily living. Cronbach's alpha was 0.795 and the intraclass correlation coefficient was reliable for the items.Conclusion: As detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG treatment in many aspects of the disease.

🔖

Cite This Article

GÜLTEKİN, M., ULUKAN, Ç., AYDEMİR, S. T., DOĞU, O., HANAĞASI, H. A., BİLGİÇ, B., TOKÇAER, A. B., ÇAKMUR, R., ELİBOL, B., MİRZA, M., GÜNAL, D., ÖZBEK, Ç. S. E., KENANGİL, G., KÜSBECİ, Ö. Y., AKBOSTANCI, M. C. (2020). Multicenter study of levodopa carbidopa intestinal gel in Parkinson's disease: the Turkish experience. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 1, 66–85. https://ajindex.com/articles/113231

📄 Full Text PDF Viewer

↗New Tab

References (1)

  1. 1. Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurology 2006; 5: 525-535. 2. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet 2009; 373: 2055-2066. 3. Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson’s disease. CNS Drugs 2010; 24: 119-129. 4. Tetrud JW. Balancing short-term symptom control and longterm functional outcomes in patients with Parkinson’s disease. CNS Spectrums 2007; 12: 275-286. 5. Stocchi F, Tagliati M, Olanow CW. Treatment of levodopainduced motor complications. Movement Disorders 2008; 23: 559-612. 6. Chang FCF, Kwan V, van der Poorten D, Mahant N, Wolfe N et al. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s disease. Journal of Clinical Neuroscience 2016; 25: 41-45. 7. Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VSC et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Movement Disorders 2015; 30: 500-509. 8. Buongiorno M, Antonelli F, Cámara A, Puente V, De FabreguesNebot O et al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. Parkinsonism & Related Disorders 2015; 21: 871-876. 9. Virhammar J, Nyholm D. Levodopa carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence experience. Therapeutic Advances in Neurological Disorders 2017; 10: 171-187. 10. Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A et al. EuroInf: A multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Movement Disorders 2015; 30: 510-516. 11. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye G et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Movement Disorders 2009; 24: 1468-1474. 12. Melgari J, Salomone G, Di Biase L, Marano M, Scrascia F et al. Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: management in clinical practice. Parkinsonism & Related Disorders 20015; 21: 327-328. 13. Slevin J, Fernandez HH, Zadikoff C, Hall C, Eaton S et al. Long-term safety and maintenance of efficacy of levodopacarbidopa intestinal gel: an open-label extension of the double blind pivotal study in adv